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Abstract 
Germline intragenic mutations in PTEN, a tumor suppressor gene located on 10q23.3 
and encoding a lipid and protein-tyrosine phosphatase, are associated with 80% of 
patients with Cowden syndrome (CS) characterized by multiple hamartomas and an 
increased risk of breast, thyroid, and endometrial cancers, and 60% of patients with 
Bannayan-Riley-Ruvalcaba syndrome (BRRS) characterized by macrocephaly, 
lipomatosis, and speckled penis. Despite extensive PCR-based PTEN mutation 
analysis in these two syndromes, the underlying genetic causes remain to be 
determined in a considerable proportion of classic CS and/or BRRS without a PCR-
detectable PTEN mutation. Because CS is believed to be without locus heterogeneity, 
we hypothesized that gross gene deletions and mutations in the PTEN promoter might 
alternatively account for a subset of apparently mutation-negative CS and/or BRRS 
patients.  Applying real-time quantitative multiplex PCR and fluorescent-based semi-
quantitative multiplex PCR assays, we identified three (2.5%) germline hemizygous 
PTEN deletions in a series of 122 apparently mutation-negative classic CS (N=96) or 
BRRS (N=26). Fine mapping of the region suggested that one deletion encompassed 
the whole gene, and the other two included exon 1 and encompassed exons 1 to 5 of 
PTEN, respectively. Two of the three deletion cases carried the diagnosis of BRRS 
and one CS.  Of note, the BRRS patient with only exon 1 deletion had mild features. 
Mutation analysis of the PTEN promoter revealed nine cases (7.4%) harboring 
heterozygous germline mutations. All nine individuals with promoter mutations had 
classic CS, representing almost 10% of all CS subjects. Eight had breast cancers 
and/or benign breast tumors, but otherwise mild features. Western blot analysis for 
PTEN protein, obtained from one deletion positive and five PTEN promoter mutation 
positive patient lymphoblast cell lines, revealed a half reduction protein level and 
multiple bands of immmunoreactive protein, respectively. In contrast, control samples 
contained only one reactive band of expected size. Further analysis revealed an 
elevated level of phosphorylated Akt in the five promoter mutation positive samples, 
compared to control cell lines, indicating that the PTEN protein present in the 
promoter mutation positive cases was not active.  Our observations suggest that 
classic BRRS without PCR-detected intragenic PTEN mutations should be offered 
deletion analysis while classic CS without PCR-detectable PTEN mutation should be 
offered promoter analysis. Protein from promoter variant positive individuals should 
be subjected to Western blot for PTEN and P-Akt to confirm pathogenicity. 
Introduction 
Cowden syndrome (CS, OMIM 158350) is an autosomal dominant disorder that is 
characterized by multiple hamartomas affecting derivatives of all three germ layers 
and by an increased risk of breast, thyroid, and endometrial neoplasia (Eng 2000).  
PTEN/MMAC1/TEP1 (OMIM 601728), a tumor suppressor gene located at 10q23.3, 
encodes a dual-specificity phosphatase which functions as a major 3’-phosphatase and 
antagonizes the phosphoinositol-3-kinase (PI3K)/Akt pro-apoptotic pathway (Nelen et 
al. 1996; Li and Sun 1997; Li et al. 1997; Steck et al. 1997; Maehama and Dixon 
1998; Stambolic et al. 1998). Via this and PI3K/Akt-independent pathways, proper 
PTEN signaling leads to G1 cell cycle arrest and/or apoptosis (Furnari et al. 1998; Li 
and Sun 1998; Stambolic et al. 1998; Weng et al. 1999; Weng et al. 2001a; Weng et 
al. 2001b; Weng et al. 2001c; Weng et al. 2001d; Weng et al. 2002). When 
ascertained strictly by the International Cowden Consortium Operational Diagnostic 
Criteria, approximately 80% of CS have been found to carry germline mutations in 
PTEN (Liaw et al. 1997; Marsh et al. 1998). In addition, germline mutations of PTEN 
have been found in 60% of individuals with Bannayan-Riley-Ruvalcaba syndrome 
(BRRS, OMIM 153480) (Marsh et al. 1997; Marsh et al. 1998; Marsh et al. 1999). 
Subsequently, the clinical spectrum of disorders that are associated with germline 
PTEN mutations has expanded to include seemingly disparate syndromes, such as 
Proteus syndrome (OMIM 176920), Proteus-like syndromes, and VATER association 
with macrocephaly (Zhou et al. 2000b; Reardon et al. 2001; Zhou et al. 2001; Smith 
et al. 2002).  
Despite extensive PTEN mutation analysis in both the research and clinical 
setting in the two autosomal dominant hamartomatous syndromes, CS and BRRS, the 
underlying genetic causes remain undetermined in 20% and 40%, respectively, of 
individuals with classic CS and/or BRRS, in whom no mutations have been detected 
by conventional mutation detection techniques, ie, PCR-based single-strand 
conformation polymorphism analysis (SSCP), denaturing gradient gel electrophoresis 
(DGGE) and direct DNA sequencing [reviewed by (Waite and Eng 2002)].  Because 
CS is believed to be without genetic heterogeneity (Nelen et al. 1996), we 
hypothesized that apparently PTEN mutation negative CS and BRRS may be 
attributed to large gene rearrangements and deletions, which cannot be detected by 
PCR-based mutation detection strategies, and promoter mutations. To test our 
hypotheses, therefore, we used a combination of real-time quantitative multiplex PCR 
analysis, fluorescent-based semi-quantitative PCR assays and microsatellite analyses 
to define and characterize PTEN and regional deletions in 122 CS and BRRS 
probands previously found not to have intragenic PTEN mutations.  Further, deletion 
negative samples were subjected to sequence analysis of the promoter region of 
PTEN.  Finally, we biochemically characterized the potential pathogenicity of the 
deletion and promoter mutations. 
 
Patients, Materials and Methods 
Subjects and DNA Extraction 
 After informed consent, peripheral blood was obtained from 122 unrelated 
individuals, who were diagnosed with CS according to the diagnostic criteria set by 
the International Cowden Consortium (Eng 2000) and BRRS by the original clinical 
definition (Gorlin et al. 1992). In addition, these subjects were found to have no 
germline mutations in the PTEN coding region, exon-intron boundaries or flanking 
intronic regions by DGGE and direct sequencing, were analyzed for gene deletions, 
duplications and promoter mutations. Overall, 96 (79%) had classic CS, and 26 (21%) 
had BRRS. Clinical phenotypic details including organ-specific cancers and benign 
processes and PHTS-related features [detailed by (Marsh et al. 1998)], were available 
for all individuals and their families. Normal controls comprised commercially 
available pooled human genomic DNA (Promega, Madison, WI) and 186 healthy 
Caucasian blood donors. Germline DNA from peripheral blood leukocytes from cases 
and controls were extracted using standard techniques (Miller et al. 1988).  In 
addition, remaining leukocytes from 32 normal controls and a subset of cases were 
EBV-transformed for lymphoblastoid cultures (Fukushima et al. 1992). 
 
Multiplex Real-Time Quantitative PCR  
 The real-time quantitative PCR and analysis were carried out using the ABI 
7700 Sequence Detector System (ABI/Perkin Elmer, Foster City, CA) as previously 
described (Sieber et al. 2002). Real-time quantitative PCR assay determines gene 
dosage (or copy number) by monitoring PCR amplification in real-time and using the 
5’-nuclease activity of Taq DNA polymerase. PTEN exons 1 and 5 were chosen as 
targets for the real-time quantitative PCR assay, while the remaining exons were 
analyzed by using a fluorescent-based semi-quantitative multiplex PCR approach as 
detailed below. Exon 8 of human RET, a proto-oncogene located at 10q11.2 which is 
not deleted or amplified in the germ-line of CS and/or BRRS patients, was chosen as 
internal control. The primers and probes were designed by using PRIMER EXPRESS 
software (Applied Biosystems). The PTEN exon 1 and exon 5 probes were labeled at 
the 5’ ends with the reporter dye FAM and at the 3’ end with the MGBNF quencher. 
The RET exon 8 probe was labeled at the 5’ end with reporter dye VIC and at the 3’ 
end with the MGBNF quencher. Primer and probe sequences are listed in Table 1. 
The real-time quantitative multiplex PCR assay was optimized according to the 
instructions in User Bulletin No.5 (Applied Biosystems, data not shown).  
The assay was carried out in 96-well optical reaction plates (Applied 
Biosystems). Briefly, DNA aliquots of 15 ng/ul were prepared for PCR. Each 
experiment included triplicate patient samples, one normal control and one deletion 
control. Each 25-ul reaction contained 1 x TaqMan Universal PCR Master mix 
(Applied Biosystems), 300 nM PTEN exon 1 or exon 5 and 100 nM RET exon 8 
forward primers, 900 nM PTEN exon 1 or 100 nM exon 5 and 300 nM RET exon 8 
reverse primers, 200 nM PTEN exon 1 or exon 5 and RET exon 8 probes, and 30 ng 
DNA.  The thermal cycling conditions were 50oC for 2 min and 95oC for 10 min, 
followed by 40 cycles of denaturing at 95oC for 15 s and annealing and extension at 
60oC for 1 min. 
The raw data obtained were analyzed using the comparative CT method (as 
described in User Bulletin No.2). After normalization against the internal control, 
RET, the PTEN copy number of a given patient was determined by comparison to a 
normal calibrator. PTEN copy number was reflected by a 2-(∆∆CT) value, where ∆∆CT 
= (CTPTEN-CTRET)sample – (CTPTEN-CTRET)normal. The ∆CT value, represented the 
mean CT value of each sample-triplicate, where CT was defined as the cycle number 
during the exponential phase at which the amplification plot crossed a fixed 
normalized emission intensity threshold (average 0.05). Samples without PTEN 
deletions were expected to give 2-(∆∆CT) values close to 1, whereas samples with 
hemizygous deletion or duplication were expected to give 2-(∆∆CT) values close to 0.5 
or 1.5, respectively. Positive results were controlled on at least three independent 
experiments.  
 
Semi-quantitative Fluorescent Multiplex PCR    
Short fragments (<300 bp) of PTEN exons 2, 3, 4, 6, 7, 8, 9 and RET exon 8, 
as an internal control, were simultaneously PCR amplified, using 6-FAM labeled 
primers (Table 1). Three multiplex PCRs were necessary to cover all of the exons. 
PCR was performed in a final volume of 25 ul containing 100 ng genomic DNA, 0.2-
1 uM of each primers, 1x Qiagen HotStartTaq multiplex PCR buffer and 0.5x Q-
solution (Qiagen, Valencia, CA). After a denaturation and ‘hot-start’ step of 15 min at 
95oC, there were 21 cycles of 30 s at 95oC, 90 s at 55oC and 90 s at 72oC, followed by 
a final extension of 10 min at 72oC. PCR products were electrophoresed on a semi-
automated sequencer (ABI-3700, Applied Biosystems), data were analyzed using the 
Gene Scanner Version 3.7 (Applied Biosystems). The peak height of the 
corresponding fragment was compared between each sample and normal control in 
the fluorescent multiplex PCR assay. A 0.5 reduction of the peak(s) indicates an 
hemizygous deletion of the corresponding exon(s), whereas exonic duplication results 
in a 1.5 increase of the peak height. Each positive sample was re-analyzed in at least 
three independent experiments.  
 
Microsatellite and SNP Analysis 
Genotypes were determined by using nine polymorphic marker loci as 
described previously (Marsh et al. 1999; Zhou et al. 2000a) (Fig. 2). Markers 
AFMa086wg9, IVS+4 109 ins/del TCTTA and IVS8+32 G/T are intragenic to PTEN, 
D10S215, D10S1765 and D10S541 are within 500 Kb up- or downstream of PTEN. 
Markers D10S573, D10S532 are located about 3 cM upstream of PTEN, and marker 
D10S583 lies about 7 cM downstream of PTEN. 
 
PTEN Promoter Mutation Analysis 
Primers were designed to amplify the full length of the PTEN promoter region 
between –1344 bp and –745 bp upstream of the translation start codon  (Sheng et al. 
2002) (Table 1). PCR was carried out in 25-ul reactions containing 1 x Qiagen 
HotStartTaq Master buffer, 1 x Q-solution (Qiagen, Valencia, CA), 0.4 nM of froward 
and reverse primers. After a denaturation and ‘hot-start’ step of 15 min at 95oC, the 
PCR consisted of 35 cycles of 30 s at 94oC, 45 s at 65oC, and 45 s at 72oC, followed 
by a final extension of 10 min at 72oC. After pre-sequencing treatment with restriction 
enzymes Exon I and SAP (USB, Cleveland, OH), PCR products were directly 
sequenced on both strands using the big Dye Terminator Kit (Applied Biosystems) 
and a model 377 automated sequencer (Applied Biosystems).  
 
Cellular Protein Extraction   
 Lymphoblast cell lines were generated by immortialization of patient and 
control lymphocytes with Cylclosporin-A, and Epstein-Barr virus.  Cells were 
maintained in RPMI containing 20% FBS and passaged as needed. Approximately 10 
million cells were pelleted by centrifugation (800 x g, 10 min, 4˚C), the resulting 
pellet was then washed twice with ice cold PBS, followed by centrifugation and 
resuspended in mammalian lysis buffer (Pierce, Rockford, IL) containing 500 mM 
PMSF, 5 µg/ml each of leupeptin, aprotinin, and pepstatin, 2 mM sodium 
orthovanadate, 50 mM NaF and 10 mM β−glycerophosphonate. Insoluble cellular 
material was removed by centrifugation at 4˚C.  Protein concentration was determined 
by the bicinchoninic acid method with bovine serum albumin as a standard (Smith et 
al. 1985). 
 
Western Blot Analysis   
Proteins (30 µg) were separated by 10% SDS-PAGE using the Laemelli 
method (Laemmli 1970), after electrophoresis, proteins were electrophoretically 
transferred to nitrocellulose (Towbin et al. 1979).  Nitrocellulose blots were blocked 
by incubation for 1 hr in 5% milk in TBS-T (10 mM Tris pH=7.0, 100 mM NaCl and 
0.1% Tween 20).  Blots were then incubated for 2 hr, at room temperature with either 
anti-PTEN or an antibody raised against the Ser 473 phosphorylated Akt (P-Akt) 
(Santa Cruz, Santa Cruz, CA).  All primary antibodies were diluted 1:1000 in 3% 
BSA.  After the primary incubation, the blots were subjected to six 10-min washes 
and then incubated for 1 hr with the appropriate HRP-conjugated secondary antibody 
at a 1:5000 dilution.  Blots were washed again, and visualized by enhanced 
chemiluminesence according to manufacturer’s instruction. 
 
Results 
Using the combination of real-time quantitative multiplex PCR and fluorescent 
multiplex PCR assays, we analyzed 122 DNA samples from individuals with classic 
CS and/or BRRS with no apparent germline intragenic PTEN mutation detected by 
PCR-based techniques. We found 3 (2.5%) individuals harboring hemizygous 
germline deletions encompassing all or part of PTEN. The 2-(∆∆CT) values ranged from 
0.45 to 0.60 for the three patients with deletions, from 0.81 to 1.35 for the deletion 
negative cases, and from 0.93 to 1.21 for the 12 normal individuals tested (Fig. 1). 
One sample (1397-1) showed deletion of all nine PTEN exons, suggesting that the 
deletion encompassed the entire gene. The other two samples (141-2 and 1621-1) had 
deletions encompassing exon 1 to 5 and exon 1 only, respectively. No sample was 
found to have exonic duplication. Further, we included a fragment of PTEN exon 5 in 
the fluorescent multiplex PCR assay as well, and found no deletions except for the 
ones detected by real-time quantitative multiplex PCR, thereby confirming the 
sensitivity of fluorescent multiplex PCR assay. 
To assess the extent of the PTEN germline deletions, three polymorphic 
markers intragenic to PTEN and six polymorphic markers flanking the 10q23.3 region 
were genotyped (Fig. 2). All 3 deletion patients were apparently homozygous 
(suggesting hemizygosity) at markers most close to or within the PTEN gene 
(D10S1765, AFMa086wg9, IVS4+109 and IVS8+32), consistent with the 
hemizygous deletions already identified by real-time quantitative multiplex PCR and 
fluorescent multiplex PCR assays. In one case (1397-1), “homozygosity” spanned 
from the upstream marker D10S1765 to D10S541, downstream of PTEN, concordant 
with whole-gene deletion detected by the real-time quantitative PCR assays, and 
suggesting a deletion which also includes all of the PTEN promoter and likely all of 
the 3’UTR. The second deletion case (141-2) showed “homozygosity” at D10S215, 
D10S1765, AFMa086wg9 and IVS4+109 and heterozygosity at IVS8+32, consistent 
with partial PTEN deletion, encompassing exon 1 to exon 5. In the third case (1621-
1), while the homozygosity spanned from D10S215 to IVS8+32, deletion was only 
found at exon 1 by real-time quantitative PCR assay, suggesting that the three 
intragenic markers are truly homozygous.  All these deletions likely extend at least 50 
kb upstream of the translational start site (D10S1765).  
Germline DNA from the remaining 119 patients without deletions were 
sequenced for mutations in the 600-bp full promoter region of PTEN. Nine patients 
(9/119, 7.6%) were found to have heterozygous sequence variants within the PTEN 
promoter region (Fig. 3). None of these promoter sequence variants were found 
among 186 normal Caucasian controls, suggesting that the former are likely 
pathogenic. Two other sequence variants (-903 G/A and –1026 C/A) were present in 
both patients and normal control individuals with similar allele frequencies (data not 
shown), suggesting that they were indeed polymorphisms.  
To functionally assess the PTEN promoter point mutations, cellular protein 
was isolated from lymphoblastoid cells lines available from five cases with promoter 
mutations and subjected to Western blot analysis.  Figure 4 shows that PTEN protein 
was recognized in control as well as case samples with promoter sequence variations. 
Control samples and a sample from a PTEN mutation negative CS patient displayed a 
single immunoreactive protein of the correct size. Interestingly, samples from patients 
carrying the promoter mutations showed a decrease in immunoreactive PTEN of the 
correct molecular weight (Fig.4A, open arrowhead), concordant with a dramatic 
increase of a slightly lower immunoreactive band (Fig. 4A, closed arrowheads).  This 
lower band is visible in the PTEN mutation negative CS sample and in an occasional 
control, however, not to the same extent as the promotor mutation samples and never 
with a loss of immunoreactivity of PTEN. Three of the five promoter mutation 
positive cases had a laddering effect with several immunoreactive bands recognized at 
both lower and higher molecular weights (Fig. 4A, astericks). We have analyzed 32 
control samples and 23 PTEN mutation negative samples and have not observed this 
laddering effect (data not shown).  These data strongly suggest that the lower 
molecular weight immunoreactive band and the laddering effect that we observe are 
specific and related to the promoter mutations in these patients. 
Because immunoreactive PTEN of the correct molecular weight was present 
in the samples containing PTEN promoter mutations, albeit to a lower extent, we 
decided to determine if this protein, or the presumably non-full-length proteins 
(laddering effect), was active. PTEN anatagonizes the PI3K/Akt pathway by 
decreasing phosphatitidylinsositol (3,4,5) triphosphate levels [reviewed by (Waite and 
Eng 2002)]. This reduction ultimately leads to reduced Akt phosphorylation 
[reviewed by (Waite and Eng 2002)]. Thus, when PTEN is active, the levels of Akt 
phosphorylation are low.  When PTEN is absent or inactive, the levels of 
phosphorylated Akt increases. Figure 4B shows that in control and PTEN mutation 
negative samples that the level of phosphorylated Akt (detected by an anti-phospho-
Akt antibody) is low to nondetectable, indicating active PTEN function. In contrast, 
the level of phosphorylated Akt in the samples from cases containing promoter 
mutations are dramatically elevated. These data indicate that the PTEN protein 
produced has inactive lipid phosphatase activity.  
All nine individuals with germline PTEN promoter mutations appear to have 
mild phenotypic features, and non-multi-organ involvement.  Interestingly, the BRRS 
subject with exon 1 and upstream deletion also posseses a relatively mild phenotype, 
with only macrocephaly and lipomas. Although based on small sample size, there is a 
trend towards gastrointestinal hamartomatous polposis in individuals with deletions 




Based on PCR-based mutation scanning technologies, 80% and 60% of classic CS 
and BRRS individuals, respectively, have been found to harbor germline intragenic 
mutations in PTEN.  All PCR-based technologies are limited by their inability to 
detect neat-single-exon deletions, large deletions and rearrangements [reviewed by 
(Eng et al. 2001); Eng, 2001 #119].  Therefore, using a combination of different 
technologies, we have found three of 122 CS/BRRS individuals previously without 
intragenic PTEN mutations to have germline deletions encompassing part or all of 
PTEN.  There is little doubt that all three deletions are functionally deleterious as all 
three likely include the promoter as well as all or part of PTEN. Protein analysis on 
one of the three deletion positive patient’s lymphoblastoid cell lines revealed about 
50% reduction in PTEN protein level, consistent with hemizygousity of PTEN (Waite 
and Eng, unpublished data). Two of these probands have gastrointestinal polyposis, 
one of whom has CS.  This is unusual as classic CS patients do not become 
symptomatic from hamartomatous polyps because these polyps are characteristically 
diminutive (Weber et al. 1998). While our patients’ deletions are not cytogenetically 
obvious, at least three other unrelated CS or BRRS patients have been reported 
previously to have deletions or rearrangements in the PTEN region detected by 
cytogenetics (Arch et al. 1997; Tsuchiya et al. 1998; Marsh et al. 1999; Ahmed et al. 
2000).  All three with cytogenetically detected PTEN deletion or rearrangements 
carried the clinical diagnosis of BRRS.  Overall, therefore, at least five BRRS 
probands have been found to have deletions of or encompassing PTEN.   
Until now, the PTEN promoter has not been examined in patients with CS 
and/or BRRS. However, in vitro work has shown that activated PPARγ, p53, and 
EGR1 have been shown to up-regulate PTEN transcription (Patel et al. 2001; 
Stambolic et al. 2001; Virolle et al. 2001), suggesting that changes to the promoter 
sequence may indeed result in changes to PTEN protein structure, levels and function. 
The genomic characterization of the PTEN promoter (Sheng et al. 2002) prompted us 
to scan for possible mutations in our apparently mutation-negative CS and/or BRRS 
patients. Among 119 mutation-negative or deletion negative CS or BRRS cases, nine 
CS probands were found to carry germ-line heterozygous point mutations in the 
promoter that were absent in 372 control chromosomes. Of significance, all nine 
individuals with PTEN promoter mutations had a diagnosis of classic CS, yet had 
relatively mild phenotypic features and oligo-organ involvement [<4 organ 
involvement: see (Marsh et al. 1998) for classification]. Interestingly, one deletion 
positive proband with exon 1 and upstream involvement had similarly mild features 
and two-organ involvement. 
Of the nine patients with 10 promoter mutations (one case had two different 
sequence variants), five were localized to the minimum PTEN promoter region (-958 
to –821), two of which (-920 G>T, -930 G>A) are predicted to alter two putative Sp1 
transcription factor binding sites (Fig. 3). Further, protein analysis revealed a reduced 
expression of wildtype PTEN, a strong lower molecular weight immunoreactive band, 
and a laddering effect of protein immunoreactive with a specific monoclonal antibody 
against human PTEN, suggesting that these point nucleotide substitutions are 
functionally significant and thus represent promoter mutations. These data suggest 
that the promoter variats may result in alternative start sites yielding PTEN protein of 
various sizes (Fig. 4A). It is interesting to note that the two samples with mutations at 
the two putative Sp1 binding sites were the two with doublet PTEN immunoreactive 
bands but no laddering effect (Fig. 4A).  Although the transcriptional regulation of 
PTEN is only now beginning to be elucidated, we suspect that these variants would 
alter PTEN transcription resulting in impaired protein expression. The presence of 
some wildtype protein together with PTEN proteins of various sizes might be 
posulated to result in the milder phenotype associated with these promoter variants.  
Another possibility is that the PTEN protein formed is also somehow altered at the 
protein level which results in targeted degradation, and it is the degradation of PTEN 
protein that we are observing. The mechanisms of PTEN degradation are only now 
being understood (Vazquez et al. 2000; Torres and Pulido 2001; Waite and Eng 
2003).  Improper PTEN degradation could also result in impaired protein expression. 
The precise mechanism for the appearance of the both the lower and higher molecular 
weight immunologically reactive PTEN species remains to be investigated. 
Regardless of the mechanism of lower molecular weight proteins, we have 
demonstrated that the PTEN protein species produced in these promoter mutation 
positive patients is not active. The levels of phosphorylated-Akt were significantly 
higher in samples haboring promoter sequence variants compared to controls and 
PTEN mutation negative samples (Fig. 4B), indicating an increase in the activity of 
the pro-proliferative PI3K/Akt pathway.   
It is interesting to note that PTEN is a dual-substrate phosphatase 
dephosphorylating both lipid and protein substrates [reviewed by (Waite and Eng 
2002)]. At this time, we can only accurately assess the lipid phosphatase activity, by 
monitoring the levels of Akt phosphorylation. While our lab has shown that the 
protein phosphatase activity of PTEN regulates the down regulation of the mitrogen-
activated protein kinase pathway (Weng et al. 2001d), we have found that the level of 
activation of this pathway varies considerably even in normal controls (Waite and 
Eng, unpublished observations).  Therefore, we are unable to reliably investigate 
changes in PTEN’s protein phosphatase activity that may arise from various PTEN 
mutations. It is interesting to postulate that various degrees of changes in both the 
lipid and protein phosphatase activities may play a role in the wide range of clinical 
manifestations of CS and BRRS.  
Overall, our data demonstrating a ~2.5% germline PTEN deletion frequency 
amongst PCR-defined PTEN mutation negative CS/BRRS might suggest that deletion 
analysis has no place in the clinical setting.  However, based on our observations and 
those in the literature, it may be prudent to offer deletion analysis, both microscopic 
and submicroscopic, in BRRS patients and CS patients with gastrointestinal polyposis 
without PCR-based intragenic PTEN mutations. Further, our ~10% promoter mutation 
frequency amongst CS probands previously found to be PCR-mutation negative and 
deletion negative does suggest that promoter analysis might be useful in the clinical 
setting when PCR-based methods yield negative results.  That these promoter variants 
are deletrious and likely causative of CS have been demonstrated by aberrant PTEN 
protein bands on Western blot resulting in activation of the pro-proliferative Akt 
pathway.  Indeed, Western analyses should be considered as a useful molecular 
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Table 1. Probes and primers used for real-time quantitative multiplex PCR and 
fluorescent multiplex PCR assays 
Primer / Probe Sequence (5’ to 3’) Amplicon size 
(bp) 
PTEN E1 Forward GAGGATGGATTCGACTTAGACTTGA 85 
Reverse  CCCACGTTCTAAGAGAGTGACAGAA  
Probe FAM-CCTGTATCCATTTCTG-MGBNF  
PTEN E5 Forward CCTACTTGTTAATTAAAAATTCAAGAGTTT
TTT 
98 
Reverse GTGGGTTATGGTCTTCAAAAGGATA  
Probe FAM-TGTGCAACTGTGGTAAA-MGBNF  
RET E8 Forward GTCCTGTGCAGTCAGCAAGAGA 79 
Reverse CCACTCACACCTGCCTGTTG  
Probe VIC-CCTCACACTCCAGCCG-MGBNF  
PTEN E2 Forward FAM-GTTTGATTGCTGCATATTTCAG 163 
Reverse TGAAATAGAAAATCAAAGCATTC  
PTEN E3 Forward FAM- AAAATCTGTCTTTTGGTTTTTC 178 
Reverse TTGCAAGCATACAAATAAGAA  
PTEN E4 Forward FAM-CATTATAAAGATTCAGGCAAT 205 
Reverse GACAGTAAGATACAGTCTATC  
PTEN E5 Forward FAM-CTTTTTACCACAGTTGCACA 282 
Reverse GGAAAGGAAAAACATCAAAA  
PTEN E6 Forward FAM-CCTGTTAAAGAATCATCTGGA 120 
Reverse AAGGATGAGAATTTCAAGCA  
PTEN E7 Forward FAM- AGGCATTTCCTGTGAAATAA 172 
Reverse TTGATATCACCACACACAGG  
PTEN E8 Forward FAM-CTCAGATTGCCTTATAATAGTC 245 
Reverse TCTGAGGTTTCCTCTGGTC  
PTEN E9 forward FAM-TCATATTTGTGGGTTTTCATT 260 
Reverse TCATGGTGTTTTATCCCTCT  
RET E8 Forward FAM-CTGTGACCCTGCTTGTCT 135 
Reverse CACTCACACCTGCCTGTT  
Promoter Forward GCGTGGTCACCTGGTCCTTT 683 





Figure 1 Real-time quantitative multiplex PCR results for 12 normal controls and 119  
apparently mutation-negative individuals with CS and/or BRRS at PTEN exon 1. 
Normal controls showed 2 -∆∆CT values between 0.93 and 1.21. Patients with two 
copies of PTEN displayed values between 0.81 and 1.35, whereas patients with only 
one copy had values between 0.45 and 0.60. 
 
Figure 2 Genotyping results for three CS and/or BRRS patients with PTEN deletions. 
 
Figure 3 Germline PTEN promoter mutations and polymorphisms found in CS 
probands. 
 
Figure 4 Aberrant immunoreactive PTEN species and increased phosphorylation of 
Akt in promotor mutation samples 
30 mg of protein from lymphoblast cell lines, generated from control or patient blood, 
was separated on a 10% SDS-PAGE gel and subjected to western analysis as 
described in the Methods.  Samples from patients with promotor mutations (P), a 
patient who is PTEN mutation negative (N) and normal controls (C) were analyzed.  
A.  Western analysis for PTEN protein. Open arrows indicate the expected molecular 
weight of PTEN, closed arrows indicate the slower migrating immunoreactive band, 
and astericks indicate bands of aberrant molecular weight.  B. Western analysis for P-
Akt. 
 
 
